Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
50 Big Debates in Gynecologic Oncology

50 Big Debates in Gynecologic Oncology

9781108940801
220,44 zł
198,39 zł Zniżka 22,05 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 198,39 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Highlighting over 50 hot topics where controversy exist in management of patients with gynecologic malignancy, this book presents expertly argued opinions for and against, incorporating current evidence and clinical trials outcomes. A diverse range of topics are included that pertain to several disciplines in gynecologic oncology, including surgical management of disease, medical oncology, immunotherapy, radiation therapy, as well as screening, preventive and palliative care. This book will be relevant to a diverse audience of practitioners and trainees including gynecologists, gynecological oncologists, surgeons, medical oncologists, radiation oncologists, and general medics. It will be a useful guide for practicing clinicians managing their patients, as well as a concise textbook for trainees and students preparing for examinations and board certifications in gynecologic oncology. Readers will gain an insight into topical controversies, critically evaluating the different sides to enhance their own clinical practice.
Szczegóły produktu
Cambridge University Press
97961
9781108940801
9781108940801

Opis

Rok wydania
2023
Numer wydania
1
Oprawa
miękka foliowana
Liczba stron
224
Wymiary (mm)
155.00 x 235.00
Waga (g)
536
  • Section I: Perioperative Management; 1A. Should routine mechanical bowel preparation be performed before primary debulking surgery? Yes Lea A. Moukarzel and Oliver Zivanovic; 1B. Should routine mechanical bowel preparation be performed before primary debulking surgery? No Shannon Armbruster and Fidel A. Valea; 2A . Should preoperative carbohydrate loading be routine prior to debulking surgery? Yes Arwa Mohammad, Deepa Maheswari M. Narasimhulu and Sean C. Dowdy; 2B. Should preoperative carbohydrate loading be routine prior to debulking surgery? No Kathryn Miller, Dib Sassine and Yukio Sonoda; Section II: Screening, Prevention and Early Diagnosis; 3A. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? Yes Thomas Boerner and Kara Long Roche; 3B. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? No Steven A. Narod; 4A. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? Yes Thomas C. Wright; 4B. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? No Ibraheem O. Awowole and Olusegun O. Badejoko; Section III: Ovarian Cancer; 5A. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? Yes Eseohi Ehimiaghe and Edward Tanner; 5B. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? No Gordon J. S. Rustin; 6A. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? Yes Ilaria Betella and Matteo Repetto; 6B. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? No Raanan Alter and Ernst Lengyel; 7A. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? Yes Rachel N. Grisham; 7B. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? No David M. Gershenson; 8A. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Observation Jason D. Wright; 8B. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Adjuvant chemotherapy Jonathan Ledermann and Sophia Wong; 9A. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Three cycles Annalisa Garbi, Eleonora Zaccarelli and Federica Tomao; 9B. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Six cycles John K. Chan and Daniel S. Kapp; 10A. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated withneoadjuvant chemotherapy: Yes Michelle Davis and Ursula Matulonis; 10B. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated with neoadjuvant chemotherapy: No Olga T. Filippova and William P. Tew; 11A. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? Yes Sven Mahner, Anca Chelariu-Raicu and Fabian Trillsch; 11B. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? No Sean Kehoe and Jason Yap; 12A. Should minimally invasive modalities be routinely/uniformly utilized for assessment of resectability prior to attempted primary debulking in patients with advanced ovarian cancer? Yes Juliet E. Wolford
Komentarze (0)